TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Iterum Therapeutics ( (ITRM) ) has issued an update.
On October 16, 2025, Iterum Therapeutics announced a prospectus supplement for the offer and sale of its ordinary shares, aiming to raise up to $20 million under its at-the-market offering agreement. The company has previously raised approximately $36.2 million through similar offerings. In August 2025, Iterum launched ORLYNVAH™ in the U.S. market, expecting modest sales in the early stages of its commercialization efforts.
The most recent analyst rating on (ITRM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Underperform.
Iterum Therapeutics faces significant financial challenges with ongoing net losses and cash flow issues, despite positive developments such as FDA approval of ORLYNVAH. The technical indicators suggest weak market momentum, and valuation metrics reflect poor investment attractiveness. The potential market for ORLYNVAH and improved financial performance are notable positives, but strategic uncertainties and financial obligations weigh heavily on the stock’s outlook.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics is a pharmaceutical company involved in the development and commercialization of anti-infective treatments. The company focuses on the U.S. market, having recently launched its product ORLYNVAH™ into the community market.
Average Trading Volume: 873,361
Technical Sentiment Signal: Sell
Current Market Cap: $32.94M
See more data about ITRM stock on TipRanks’ Stock Analysis page.